Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Cabaletta Bio Inc Market Cap
From what 12 stock analysts predict, the share price for Cabaletta Bio Inc (CABA) might increase by 569.7% in the next year. This is based on a 12-month average estimation for CABA. Price targets go from $10 to $35. The majority of stock analysts believe CABA is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
CABA is a stock in Healthcare which has been forecasted to be worth $22.1 as an average. On the higher end, the forecast price is $35 USD by Derek Archila from Wells Fargo and on the lower end CABA is forecasted to be $10 by Vamil Divan from Mizuho.
These are the latest 20 analyst ratings of CABA.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Douglas Tsao HC Wainwright & Co. | Buy | $25 | Reiterates | Nov 18, 2024 |
| Derek Archila Wells Fargo | Overweight | $12 | Maintains | Nov 15, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $25 | Reiterates | Nov 15, 2024 |
| Trung Huynh UBS | Buy | $10 | Initiates | Oct 10, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $25 | Reiterates | Sep 17, 2024 |
| Derek Archila Wells Fargo | Overweight | $20 | Maintains | Aug 12, 2024 |
| Gavin Clark-Gartner Evercore ISI Group | Outperform | $15 | Maintains | Aug 12, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $25 | Maintains | Aug 9, 2024 |
| Josh Schimmer Cantor Fitzgerald | Overweight | $50 | Reiterates | Jun 21, 2024 |
| Ben Burnett Stifel | Buy | $32 | Maintains | Jun 17, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $30 | Reiterates | Jun 14, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $30 | Reiterates | May 24, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $30 | Reiterates | May 16, 2024 |
| Joshua Schimmer Cantor Fitzgerald | Overweight | $50 | Reiterates | Apr 5, 2024 |
| Samantha Semenkow Citigroup | Buy | $30 | Maintains | Apr 4, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $30 | Maintains | Mar 22, 2024 |
| Derek Archila Wells Fargo | Overweight | $35 | Maintains | Mar 22, 2024 |
| Joshua Schimmer Cantor Fitzgerald | Overweight | $50 | Reiterates | Mar 22, 2024 |
| Kelly Shi Jefferies | Buy | $36 | Initiates | Feb 5, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $25 | Reiterates | Nov 29, 2023 |
When did it IPO
2019
Staff Count
136
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Steven A. Nichtberger M.D.
Market Cap
$161.1M
In 2023, CABA generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that CABA's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 22 Oct 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Cabaletta Bio shares are considered a speculative investment ahead of clinical trial updates for CAR-T therapies. The company's strong cash position may support a bullish outlook.
Why It Matters - Cabaletta Bio's potential clinical trial updates may drive significant stock price increases, presenting a high-risk, high-reward opportunity amid volatility and strong cash reserves.
Wed, 25 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Cabaletta Bio, Inc. (Nasdaq: CABA) will present new clinical data on its investigational therapy CABA-201 at the ACR Convergence 2024 from November 14-19, focusing on autoimmune disease treatments.
Why It Matters - Cabaletta Bio's upcoming presentations on CABA-201 at ACR Convergence 2024 may influence investor sentiment by showcasing potential advancements in its clinical trials and market positioning in autoimmune therapies.
Wed, 28 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Cabaletta Bio, Inc. (Nasdaq: CABA) will participate in several investor conferences in September, focusing on targeted cell therapies for autoimmune diseases.
Why It Matters - Cabaletta Bio's participation in investor conferences may enhance visibility, attract potential investors, and signal progress in its therapeutic developments, impacting stock performance.
Thu, 08 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - As of August 5, 2024, nine patients are enrolled in the RESET™ clinical development program, with 22 U.S. sites actively enrolling, including four new patients since EULAR in June.
Why It Matters - The enrollment of patients in the RESET™ program suggests progress in clinical trials, potentially leading to new treatments and impacting the company's stock value and market perception.
Tue, 02 Jul 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Cabaletta Bio, Inc. (Nasdaq: CABA) CEO Steven Nichtberger will participate in a fireside chat at the Stifel 2024 Virtual Cell Therapy Forum on July 9, 2024, at 1:00 p.m. ET.
Why It Matters - Cabaletta Bio's participation in the forum highlights its commitment to advancing innovative therapies, potentially influencing investor sentiment and stock performance in the biotech sector.
Fri, 28 Jun 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Cabaletta Bio's CABA-201 shows promise in autoimmune treatments. Despite a stock rise due to positive data, shares fell in 2024 amid slow progress and manufacturing issues.
Why It Matters - Cabaletta Bio's stock volatility reflects market sentiment on its CABA-201 therapy amid manufacturing issues and mixed data, impacting investor confidence and future valuations.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
